A Phase II Study of Temsirolimus and Erlotinib in Patients With Recurrent and/or Metastatic, Platinum-Refractory Head and Neck Squamous Cell Carcinoma

Oral Oncology - United Kingdom
doi 10.1016/j.oraloncology.2012.12.016
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Genetic Landscape of Metastatic and Recurrent Head and Neck Squamous Cell Carcinoma

Journal of Clinical Investigation
Medicine
2016English

Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/Ii Clinical Study

Oncologist
Cancer ResearchMedicineOncology
2016English

Pcn105 - Economic Burden of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Socioeconomic Factors and Survival in Patients With Non-Metastatic Head and Neck Squamous Cell Carcinoma

Cancer Science
Cancer ResearchMedicineOncology
2017English

Pcn268 - Treatments and Health Care Utilisation (Hcu) in Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (Hnscc) Following Initial Platinum Therapy in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A Phase II Evaluation of a 3-Hour Infusion of Paclitaxel, Cisplatin, and 5-Fluorouracil in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

Cancer
Cancer ResearchOncology
2006English

Current Recommendations for Systemic Therapy of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2011English

SUPREME-HN: A Retrospective Biomarker Study Assessing the Prognostic Value of PD-L1 Expression in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2019English

Phase 2 Study of Apatinib, a Novel VEGFR Inhibitor in Patients With Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Head and Neck: Preliminary Results

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy